immunosuppressive drugs – Page 3 – Communicable Diseases Research

Approach to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis

Immunology

Published on 2021-06-212022-11-01
Journal: Frontiers in Immunology [Category] COVID-19, MERS, SARS,

The role of antirheumatics in patients with COVID-19

Review article

Published on 2021-06-012022-10-05
Journal: The Lancet Rheumatology [Category] 임상,

[키워드] absence acute respiratory distress affected Anti-inflammatory anti-rheumatic drug Baricitinib Clinical characteristics clinical trial clinical utility comparability COVID-19 COVID-19 pandemic COVID-19 related mortality death defined Dexamethasone disease drug Efficacy and safety Evidence glucocorticoid heterogeneity hospitalised patient hyperinflammation Hypothesis identify immune immune response immunosuppressive drugs inclusion criteria inhibitor initial interleukin-6 less management optimal dose organ support oxygen support Patient patients with COVID-19 patients with moderate reduce review rheumatological risk severe COVID-19 shown Stage subsequent suggested syndrome therapy Time to recovery Treatment Trial
[DOI] 10.1016/S2665-9913(21)00062-X [Article Type] Review article

The proportion and effect of corticosteroid therapy in patients with COVID-19 infection: A systematic review and meta-analysis

COVID-19 감염 환자에서 코르티코스테로이드 요법의 비율과 효과: 체계적인 검토 및 메타 분석

Meta-Analysis

Published on 2021-04-212022-09-10
Journal: PLoS ONE [Category] MERS, SARS, 임상,

[키워드] 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus addition Analysis Anti-inflammatory articles China clinical trial clinical trials Comprehensive conducted Controlled coronavirus coronavirus disease Coronavirus disease 2019 Corticosteroid corticosteroid therapy corticosteroid treatment Corticosteroids COVID-19 COVID-19 patient COVID-19 patients demonstrated died effect size Efficacy evaluate extreme ICU immunosuppressive drug immunosuppressive drugs IMPROVE indicate Infection intensive care intensive care unit journal literature review mean difference Meta-analysis Mortality network no significant difference not correlated objective observational studies observational study Odds ratio outcome outcome measure outcome measures outcomes Patient patients treated patients with COVID-19 performed proportion proportions receive registry reported Research respiratory Result severe acute respiratory syndrome Coronavirus significantly significantly higher significantly lower stratified Subgroup analyses subject systematic review The effect size those who survived treated Treatment treatment of COVID-19 Trial use of corticosteroid Viral viral clearance
[DOI] 10.1371/journal.pone.0249481 PMC 바로가기 [Article Type] Meta-Analysis

COVIDENZA – A prospective, multicenter, randomized PHASE II clinical trial of enzalutamide treatment to decrease the morbidity in patients with Corona virus disease 2019 (COVID-19): a structured summary of a study protocol for a randomised controlled trial

COVIDENZA - 코로나 바이러스 질병 2019(COVID-19) 환자의 이환율을 감소시키기 위한 엔잘루타미드 치료의 전향적, 다기관, 무작위 PHASE II 임상 시험: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2021-03-162022-09-10
Journal: Trials [Category] SARS, 임상, 치료제,

[키워드] 7-point ordinal scale age androgen Androgen receptor androgen signalling antiandrogen anticipated approved Blinding Breast cancer breast-feeding cardiovascular disease center clinical trial comparator comparator Patients Complete connection Corona virus COVID-19 COVID-19 patient COVID-19 symptom COVID-19 symptoms decrease discharge disease dissemination element enzalutamide enzyme evaluate exclusion criteria expression FIVE focus followed by for inclusion hospital hospitalised host cell Hypothesis Identifier identify immunosuppressive drugs IMPROVE include Inclusion independent intensive care interim analysis Laboratory Major majority male mechanical ventilation men morbidity multicenter multicentre North number objective observation Open-label open-label trial Ordinal Scale outcome participant Participants Patient PCR Placebo power pregnant women primary endpoint primary endpoints PROC Prostate protocol randomisation list randomised randomised controlled trial Randomized receptor Region Registered Sample size SARS-CoV-2 host cell SAS Institute SAS version 9.4 Sex Standard of care status stratified Study protocol subject supplementary material symptomatic Testosterone TMPRSS2 to define treated Treatment treatment arm Trial university Västerbotten website with COVID-19 women
[DOI] 10.1186/s13063-021-05137-4 PMC 바로가기 [Article Type] Letter

Effect of dexamethasone in patients with ARDS and COVID-19 – prospective, multi-centre, open-label, parallel-group, randomised controlled trial (REMED trial): A structured summary of a study protocol for a randomised controlled trial

ARDS 및 COVID-19 환자에서 덱사메타손의 효과 – 전향적, 다기관, 공개 라벨, 병렬 그룹, 무작위 대조 시험(REMED 시험): 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2021-03-012022-09-10
Journal: Trials [Category] SARS, 임상, 치료기술,

[키워드] (C-reactive protein 24 hour 24 hours administration adrenal gland Adult patients Adverse adverse events age alcohol allergy allocation Antigen ARDS ARDS patients ARMS assumed Barthel Index benzyl alcohol Berlin Berlin criteria Blinding Block randomisation Brazil Breastfeeding C-reactive protein calculated can be used Cardiac arrest Care carried case report form CCI Charlson Comorbidity Index Chemotherapy clinical Comorbidity comparator completion condition conducted consequence Contraception control group Corticosteroid Corticosteroids COVID-19 COVID-19 ARDS patient criteria CRP current Czech Republic Day decision defined detect Dexamethasone dexamethasone 6 mg diagnosed dissemination dose doses Dynamics eCRF Effect Effectiveness Efficacy and safety electronic case report form element eligible Endpoint enrolled enrolment EudraCT evaluate event expected exploratory Factor followed by French gastrointestinal bleeding HFNC hospital hospital discharge Hospital stay hypersensitivity Hypothesis ICU ICU admission ICUs Identifier Immunosuppression immunosuppressive drug immunosuppressive drugs Independence independent independent of Infection infections Inflammatory infusion intensive care unit intensive care units Intervention intervention group intractable intravenously intubate intubation investigational medicinal product investigator investigators Laboratory life malignancy marker mechanical ventilation medical history moderate moderate to severe Mortality nasal nasal cannula number objective observational study once daily Open-label open-label trial outcome oxygen Oxygen therapy PaO parallel-group participant Participation Patient patients with ARDS patients with moderate performed power power of 80% Pragmatic Pregnancy present primary efficacy endpoint primary endpoint protocol Quality of life randomisation randomised randomised controlled trial receive recruitment Registered routine clinical practice RT-PCR Sample size scale secondary Secondary endpoints Septic shock sequence severe ARDS sexual abstinence solution Standard deviation statistical analysis statistician status Stratification stratified Study protocol superinfection supplementary material systemic systemic corticosteroids thrombotic Thrombotic complications title Treatment treatment arm Trial Trial registration two-sided type I type I error university hospital Ventilation ventilator-free day Ventilator-free days Version VFD website WHO
[DOI] 10.1186/s13063-021-05116-9 PMC 바로가기 [Article Type] Letter

Oral Complications of ICU Patients with COVID-19: Case-Series and Review of Two Hundred Ten Cases

Review

Published on 2021-02-042022-10-30
Journal: Journal of Clinical Medicine [Category] COVID-19,

[키워드] addition affecting approach candidiasis Characteristics Co-infection Cochrane Library Complication complications coronavirus disease Course COVID-19 COVID-19 patient COVID-19 patients Critical care Critically ill Critically ill patient Dermatology described epidemiological evaluate Evidence Google Scholar healthcare ICU ICU patient ICUs immunosuppressive drugs intensive care unit life-threatening Macroglossia management mechanical ventilation necrotic nine Nurse oral oral candidiasis oral manifestations OVID Pathogens pathophysiological Perioral pressure ulcer Prevalence Prone position prone positioning reported Research review risk factor Slovakia susceptible tongue with COVID-19
[DOI] 10.3390/jcm10040581 PMC 바로가기 [Article Type] Review

Characteristics of COVID-19 infection and antibody formation in patients known at a tertiary immunology department

Short communication

Published on 2021-01-292022-10-30
Journal: Journal of Translational Autoimmunity [Category] COVID-19,

[키워드] antibodies antibody formation auto-immune disease B-cell Care clinical cohort of patient collected data common conducted Course COVID-19 COVID-19 infection COVID-19 positive patient detectable disease disease course hospital hyperinflammatory state Immunocompromised immunocompromised individuals Immunocompromised patient Immunocompromised patients immunodeficiency immunodeficient patients Immunologic deficiency syndromes immunology Immunosuppressive agents immunosuppressive drug immunosuppressive drugs incidence of COVID-19 indicate knowledge nasal swab Netherlands observation outpatient clinic pandemic Patient PCR positive PROTECT recommendation Research Result SARS-CoV-2 SARS-CoV-2 antibodies SARS-CoV-2 antibody severe disease course shown the disease therapy variable were measured with COVID-19
[DOI] 10.1016/j.jtauto.2021.100084 PMC 바로가기 [Article Type] Short communication

Immunosuppressive drugs for patients with psoriasis during the COVID-19 pandemic era. A review

Review

Published on 2021-01-012023-07-11
Journal: Dermatologic therapy [Category] SARS,

[키워드] COVID-19 cyclosporine IL12/23 inhibitors IL17-inhibitors immunosuppressive drugs jak inhibitors methotrexate psoriasis review risk of infection TNFα inhibitors
[DOI] 10.1111/dth.14498 [Article Type] Review

Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: a population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platform

Articles

Published on 2020-11-052022-10-29
Journal: The Lancet Rheumatology [Category] COVID-19,

[키워드] 95% CI absolute difference acute respiratory syndrome age Analysis association biologic clinical study coronavirus COVID-19 COVID-19 mortality COVID-19 outbreak Cox regression cumulative death deaths disease Effect Effectiveness England epithelial cell Estimated evaluate Evidence finding funding General population geographical region Hydroxychloroquine immunosuppressive drugs in vitro indicated information inhibit Interaction Medical Research Council Model Mortality National negative control Non-COVID-19 Older OpenSAFELY outcome Patient patients with COVID-19 platform population-based cohort prevention of COVID-19 primary care Prophylactic Randomised trial reduced Registered rheumatoid arthritis rheumatological risk of COVID-19 robust SARS-CoV-2 Sex shown systemic lupus erythematosus the disease Treatment use of hydroxychloroquine with COVID-19
[DOI] 10.1016/S2665-9913(20)30378-7 PMC 바로가기 [Article Type] Articles

Utility and risk of dermatologic medications during the COVID-19 pandemic

COVID-19 전염병 동안 피부과 약물의 유용성과 위험

Review

Published on 2020-11-012022-09-11
Journal: Dermatologic therapy [Category] SARS, 치료제,